Cargando…

Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups

In patients with high-grade serous ovarian cancer (HGSC), it is unclear which genomic features are related to complete gross resection (R0), which is typically associated with better clinical outcomes, or response to neoadjuvant chemotherapy (NACT). In this study, we evaluated T cell receptor (TCR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sanghoon, Zhao, Li, Little, Latasha D., Westin, Shannon N., Jazarei, Amir A., Fleming, Nicole D., Zhang, Jianhua, Futreal, P. Andrew, Sood, Anil K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840469/
https://www.ncbi.nlm.nih.gov/pubmed/33537658
http://dx.doi.org/10.1016/j.isci.2021.102053
_version_ 1783643581073850368
author Lee, Sanghoon
Zhao, Li
Little, Latasha D.
Westin, Shannon N.
Jazarei, Amir A.
Fleming, Nicole D.
Zhang, Jianhua
Futreal, P. Andrew
Sood, Anil K.
author_facet Lee, Sanghoon
Zhao, Li
Little, Latasha D.
Westin, Shannon N.
Jazarei, Amir A.
Fleming, Nicole D.
Zhang, Jianhua
Futreal, P. Andrew
Sood, Anil K.
author_sort Lee, Sanghoon
collection PubMed
description In patients with high-grade serous ovarian cancer (HGSC), it is unclear which genomic features are related to complete gross resection (R0), which is typically associated with better clinical outcomes, or response to neoadjuvant chemotherapy (NACT). In this study, we evaluated T cell receptor (TCR) repertoire diversity in primary and metastatic tumor samples (n = 90) from clinically well-annotated patients with HGSC who achieved R0 or received NACT with excellent or poor response based on a laparoscopic triage algorithm. TCR sequencing followed by an integrative analysis with comprehensive multi-omics data identified higher TCR diversity (e.g., higher number of unique productive sequences and less clonal relatedness) in the R0 than NACT groups. We found enrichment of specific TCRβ genes usage, distinct mutual exclusiveness and co-occurrence pattern of TCRβ genes among the groups. We also found significantly positive correlations between clonal relatedness and neoantigens, copy number variations, and mutation load in the groups.
format Online
Article
Text
id pubmed-7840469
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78404692021-02-02 Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups Lee, Sanghoon Zhao, Li Little, Latasha D. Westin, Shannon N. Jazarei, Amir A. Fleming, Nicole D. Zhang, Jianhua Futreal, P. Andrew Sood, Anil K. iScience Article In patients with high-grade serous ovarian cancer (HGSC), it is unclear which genomic features are related to complete gross resection (R0), which is typically associated with better clinical outcomes, or response to neoadjuvant chemotherapy (NACT). In this study, we evaluated T cell receptor (TCR) repertoire diversity in primary and metastatic tumor samples (n = 90) from clinically well-annotated patients with HGSC who achieved R0 or received NACT with excellent or poor response based on a laparoscopic triage algorithm. TCR sequencing followed by an integrative analysis with comprehensive multi-omics data identified higher TCR diversity (e.g., higher number of unique productive sequences and less clonal relatedness) in the R0 than NACT groups. We found enrichment of specific TCRβ genes usage, distinct mutual exclusiveness and co-occurrence pattern of TCRβ genes among the groups. We also found significantly positive correlations between clonal relatedness and neoantigens, copy number variations, and mutation load in the groups. Elsevier 2021-01-09 /pmc/articles/PMC7840469/ /pubmed/33537658 http://dx.doi.org/10.1016/j.isci.2021.102053 Text en © 2021 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Lee, Sanghoon
Zhao, Li
Little, Latasha D.
Westin, Shannon N.
Jazarei, Amir A.
Fleming, Nicole D.
Zhang, Jianhua
Futreal, P. Andrew
Sood, Anil K.
Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
title Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
title_full Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
title_fullStr Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
title_full_unstemmed Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
title_short Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
title_sort distinct t cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840469/
https://www.ncbi.nlm.nih.gov/pubmed/33537658
http://dx.doi.org/10.1016/j.isci.2021.102053
work_keys_str_mv AT leesanghoon distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT zhaoli distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT littlelatashad distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT westinshannonn distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT jazareiamira distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT flemingnicoled distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT zhangjianhua distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT futrealpandrew distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups
AT soodanilk distincttcellreceptorrepertoirediversityofclinicallydefinedhighgradeserousovariancancertreatmentsubgroups